Saturna Capital CORP Holds Stake in Eli Lilly and Company (LLY)
Saturna Capital CORP held its position in shares of Eli Lilly and Company (NYSE:LLY) during the first quarter, according to its most recent filing with the SEC. The institutional investor owned 1,244,300 shares of the company’s stock at the end of the first quarter. Eli Lilly and accounts for 3.6% of Saturna Capital CORP’s portfolio, making the stock its largest position. Saturna Capital CORP’s holdings in Eli Lilly and were worth $104,658,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently modified their holdings of LLY. BlackRock Inc. boosted its position in shares of Eli Lilly and by 2,628.5% in the first quarter. BlackRock Inc. now owns 62,260,488 shares of the company’s stock valued at $5,236,731,000 after buying an additional 59,978,664 shares in the last quarter. Beutel Goodman & Co Ltd. bought a new position in shares of Eli Lilly and during the first quarter valued at $161,084,000. Vanguard Group Inc. boosted its position in shares of Eli Lilly and by 3.3% in the first quarter. Vanguard Group Inc. now owns 68,597,006 shares of the company’s stock valued at $5,769,694,000 after buying an additional 2,181,701 shares in the last quarter. Winslow Capital Management LLC raised its stake in Eli Lilly and by 79.7% in the first quarter. Winslow Capital Management LLC now owns 3,875,968 shares of the company’s stock valued at $326,008,000 after buying an additional 1,719,538 shares during the last quarter. Finally, Renaissance Technologies LLC raised its stake in Eli Lilly and by 93.6% in the first quarter. Renaissance Technologies LLC now owns 2,980,400 shares of the company’s stock valued at $250,681,000 after buying an additional 1,441,200 shares during the last quarter. Institutional investors and hedge funds own 75.61% of the company’s stock.
Shares of Eli Lilly and Company (LLY) traded down 0.47% during trading on Friday, hitting $81.15. 2,446,392 shares of the company were exchanged. Eli Lilly and Company has a 12 month low of $64.18 and a 12 month high of $86.72. The stock has a market cap of $85.61 billion, a P/E ratio of 35.11 and a beta of 0.34. The company’s 50-day moving average price is $82.91 and its 200 day moving average price is $81.72.
Eli Lilly and (NYSE:LLY) last posted its earnings results on Tuesday, July 25th. The company reported $1.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.05 by $0.06. The firm had revenue of $5.82 billion during the quarter, compared to analyst estimates of $5.60 billion. Eli Lilly and had a net margin of 11.12% and a return on equity of 28.71%. Eli Lilly and’s revenue was up 7.8% on a year-over-year basis. During the same period in the previous year, the business posted $0.86 EPS. On average, equities analysts predict that Eli Lilly and Company will post $4.16 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Friday, September 8th. Shareholders of record on Tuesday, August 15th will be given a dividend of $0.52 per share. The ex-dividend date of this dividend is Friday, August 11th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.56%. Eli Lilly and’s dividend payout ratio (DPR) is 90.04%.
Several analysts have recently commented on LLY shares. Goldman Sachs Group, Inc. (The) reaffirmed a “buy” rating and set a $92.00 price target on shares of Eli Lilly and in a research report on Tuesday, May 16th. BMO Capital Markets set a $71.00 price target on shares of Eli Lilly and and gave the company a “sell” rating in a research report on Tuesday, April 25th. Zacks Investment Research lowered shares of Eli Lilly and from a “buy” rating to a “hold” rating in a research report on Tuesday, April 18th. Credit Suisse Group reaffirmed an “outperform” rating and set a $87.00 price target on shares of Eli Lilly and in a research report on Wednesday, April 19th. Finally, Argus lowered shares of Eli Lilly and from a “buy” rating to a “hold” rating and lifted their price target for the company from $64.18 to $81.00 in a research report on Thursday, April 27th. They noted that the move was a valuation call. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and twelve have assigned a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $88.27.
In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 220,000 shares of the business’s stock in a transaction dated Monday, July 31st. The shares were sold at an average price of $83.09, for a total transaction of $18,279,800.00. Following the sale, the insider now directly owns 124,049,283 shares in the company, valued at approximately $10,307,254,924.47. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Michael J. Harrington sold 22,833 shares of the business’s stock in a transaction dated Friday, June 9th. The stock was sold at an average price of $79.97, for a total transaction of $1,825,955.01. Following the sale, the vice president now owns 62,056 shares in the company, valued at $4,962,618.32. The disclosure for this sale can be found here. Insiders have sold a total of 669,733 shares of company stock worth $55,845,287 over the last 90 days. 0.20% of the stock is owned by insiders.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.